Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vaccine Safety Screening For Adventitious Agents Looms Large At Substrates Cmte.

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Vaccine and Related Biological Products Advisory Committee will examine the role of emerging technologies for detecting adventitious agents in assessing whether novel human tumor-derived cell-line substrates are suitable for vaccine production.

You may also be interested in...



Vaccine Manufacturers Need Plans To Cut Adventitious Agents By October

FDA is sending two rounds of letters to different sets of companies asking for the plans as part of the fall-out from the issues seen in rotavirus vaccines.

Vaccines Face Unknown Contamination Risks, But Need Well-Defined Testing

The discovery of adventitious porcine virus in Merck's RotaTeq and GlaxoSmithKline's Rotarix is setting off a scramble among vaccine manufacturers and FDA to come up with validated procedures to detect and deal with such undesirable agents

Porcine Virus In Merck's RotaTeq Raises Questions Of Timing, Testing

Revealed on the eve of an advisory committee meeting about safety of GSK's rival vaccine Rotarix, finding suggests that FDA and industry have considerable work to do on viral testing techniques.

Topics

Related Companies

UsernamePublicRestriction

Register

PS074656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel